Atomoxetine and the risk of mania: a case report on bipolar disorder in an ADHD patient and its dilemmas.

Int J Psychiatry Clin PractApr 28, 2026 (epub)
Case ReportPsychiatry

Ekrem Furkan Uçak, Orçun Öztürk

✦ AI-curated · Sources linked

Case in brief

A 20-year-old male with a history of ADHD, treated with atomoxetine and risperidone, developed manic symptoms following a depressive episode after bereavement. While continuing atomoxetine at 80 mg/day and reducing risperidone to 1 mg/day, manic symptoms emerged. The Naranjo scale suggested a possible link between atomoxetine and mania, but temperament traits and stressors likely played a role. Mood stabilization was achieved with lithium.

Diagnostic / clinical pearl

Clinicians should be aware that atomoxetine may contribute to mood destabilization in patients with underlying bipolar disorder, especially when adjusting antipsychotic medications.

Why it matters

This case highlights the importance of monitoring temperament and mood stability in ADHD patients, as overlapping symptoms can complicate the diagnosis of bipolar disorder.

Source

PubMed · PMID 42047475

Published in Int J Psychiatry Clin Pract. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.